What is Zacks Research’s Forecast for TNXP Q1 Earnings?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Analysts at Zacks Research issued their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on Monday, March 23rd. Zacks Research analyst D. Bautz expects that the company will earn ($3.14) per share for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals’ Q2 2026 earnings at ($2.75) EPS, Q3 2026 earnings at ($2.48) EPS, Q4 2026 earnings at ($2.32) EPS, FY2026 earnings at ($10.52) EPS and FY2027 earnings at ($3.70) EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The business had revenue of $5.39 million for the quarter, compared to analyst estimates of $2.97 million. Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%.

Several other research analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen raised Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Tonix Pharmaceuticals Trading Down 8.3%

Shares of TNXP opened at $13.75 on Thursday. The stock has a market cap of $184.25 million, a PE ratio of -0.96 and a beta of 1.88. Tonix Pharmaceuticals has a 1 year low of $13.07 and a 1 year high of $69.97. The stock has a 50 day simple moving average of $15.50 and a 200-day simple moving average of $18.11.

Insider Activity

In other Tonix Pharmaceuticals news, CEO Seth Lederman bought 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were bought at an average price of $14.89 per share, with a total value of $223,350.00. Following the purchase, the chief executive officer owned 15,001 shares of the company’s stock, valued at $223,364.89. This trade represents a 1,500,000.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.03% of the company’s stock.

Institutional Trading of Tonix Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Man Group plc bought a new stake in Tonix Pharmaceuticals in the fourth quarter valued at about $288,000. Engineers Gate Manager LP grew its holdings in Tonix Pharmaceuticals by 63.7% during the fourth quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock valued at $223,000 after purchasing an additional 5,550 shares during the period. Balyasny Asset Management L.P. bought a new stake in Tonix Pharmaceuticals in the fourth quarter valued at approximately $2,895,000. AQR Capital Management LLC acquired a new stake in Tonix Pharmaceuticals in the fourth quarter worth $313,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Tonix Pharmaceuticals in the fourth quarter worth $171,000. Institutional investors own 82.26% of the company’s stock.

Key Stories Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: Tonix announced the first participant was dosed in an investigator‑initiated Phase 1 pharmacodynamic study of TNX‑1900 (intranasal potentiated oxytocin) to assess potential for migraine and craniofacial pain. The program targets trigeminal neurovascular reactivity and uses laser speckle contrast imaging (LSCI) to measure forehead skin blood flow; preclinical data show intranasal oxytocin can block CGRP release, suggesting a mechanism distinct from existing CGRP drugs — a meaningful clinical/commercial differentiator if clinical signals are positive. Read More.
• Neutral Sentiment: Media outlets (Yahoo/Business Insider/TipRanks) are carrying the dosing news, increasing visibility for the TNX‑1900 program but with the caveat that this is an early, investigator‑initiated PD study rather than a registrational trial. Read More.
• Negative Sentiment: Zacks Research substantially lowered near‑ and medium‑term EPS forecasts (FY2026 and FY2027 cuts), reflecting expectations of continued large losses and cash consumption; the firm now models deep negative EPS for 2026 and reduced FY2027 projections. Those downgrades (and Tonix’s prior quarterly EPS miss and negative margins) increase the risk that the company will need to raise capital, which could dilute shareholders and pressure the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.